Injection, alemtuzumab
Products billed under this code include Lemtrada.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Lemtrada.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Lemtrada | Genzyme Corporation | 58468-0200-01 | 12 | $30,074.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2,506.20 | −$38.737 | 1 MG | Injection, alemtuzumab | v1, posted September 17, 2026 |
| 3Q26 | $2,544.937 | +$104.522 | 1 MG | Injection, alemtuzumab | v1, posted September 15, 2026 |
| 2Q26 | $2,440.415 | −$6.687 | 1 MG | Injection, alemtuzumab | v1, posted September 15, 2026 |
| 1Q26 | $2,447.102 | +$17.211 | 1 MG | Injection, alemtuzumab | v1, posted September 15, 2026 |
| 4Q25 | $2,429.891 | −$10.811 | 1 MG | Injection, alemtuzumab | v1, posted September 8, 2026 |
| 3Q25 | $2,440.702 | −$0.791 | 1 MG | Injection, alemtuzumab | v1, posted March 10, 2026 |
| 2Q25 | $2,441.493 | +$28.135 | 1 MG | Injection, alemtuzumab | v1, posted March 10, 2026 |
| 1Q25 | $2,413.358 | +$75.665 | 1 MG | Injection, alemtuzumab | v1, posted December 19, 2025 |
| 4Q24 | $2,337.693 | −$11.143 | 1 MG | Injection, alemtuzumab | v1, posted June 11, 2025 |
| 3Q24 | $2,348.836 | +$1.254 | 1 MG | Injection, alemtuzumab | v1, posted June 11, 2025 |
| 2Q24 | $2,347.582 | +$23.238 | 1 MG | Injection, alemtuzumab | v1, posted March 11, 2025 |
| 1Q24 | $2,324.344 | +$31.574 | 1 MG | Injection, alemtuzumab | v1, posted December 19, 2024 |
| 4Q23 | $2,292.77 | +$9.042 | 1 MG | Injection, alemtuzumab | v1, posted October 10, 2024 |
| 3Q23 | $2,283.728 | +$48.348 | 1 MG | Injection, alemtuzumab | v1, posted June 5, 2024 |
| 2Q23 | $2,235.38 | −$9.539 | 1 MG | Injection, alemtuzumab | v1, posted February 23, 2024 |
| 1Q23 | $2,244.919 | +$37.758 | 1 MG | Injection, alemtuzumab | v1, posted December 6, 2023 |
| 4Q22 | $2,207.161 | +$12.672 | 1 MG | Injection, alemtuzumab | v1, posted June 22, 2023 |
| 3Q22 | $2,194.489 | +$45.491 | 1 MG | Injection, alemtuzumab | v1, posted June 9, 2023 |
| 2Q22 | $2,148.998 | +$19.85 | 1 MG | Injection, alemtuzumab | v1, posted December 14, 2022 |
| 1Q22 | $2,129.148 | +$42.829 | 1 MG | Injection, alemtuzumab | v1, posted June 8, 2022 |
| 4Q21 | $2,086.319 | +$33.844 | 1 MG | Injection, alemtuzumab | v1, posted June 2, 2022 |
| 3Q21 | $2,052.475 | +$29.487 | 1 MG | Injection, alemtuzumab | v1, posted June 2, 2022 |
| 2Q21 | $2,022.988 | +$5.539 | 1 MG | Injection, alemtuzumab | v1, posted March 1, 2022 |
| 1Q21 | $2,017.449 | – | 1 MG | Injection, alemtuzumab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.